Last reviewed · How we verify
IM Glucagon
At a glance
| Generic name | IM Glucagon |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study Comparing User Experience of Different Delivery Devices for Glucagon (PHASE1)
- A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus (PHASE3)
- Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults (PHASE3)
- A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus (PHASE1)
- Evaluate the Immunogenicity of a Novel Glucagon Formulation (PHASE3)
- Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes (PHASE2, PHASE3)
- Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers (PHASE1)
- Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IM Glucagon CI brief — competitive landscape report
- IM Glucagon updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI